ANI Egetis Offer: What Is ANI Paying and When Could It Close?

ANI Pharmaceuticals is offering SEK 11.25 in cash for each share in Egetis Therapeutics. ANI puts the total value of the ANI Egetis offer at about SEK 5.6 billion, or about $560 million. The offer was announced on 5 November 2026 and has not completed. The acceptance period is expected to run from about 20 November to about 18 December 2026. If the conditions are met, ANI expects settlement to begin on or around 29 December 2026.

Egetis is a Stockholm-based rare disease company listed on Nasdaq Stockholm. Its lead product is Emcitate (tiratricol), approved in the EU and the US for use in MCT8 deficiency. The Egetis board unanimously recommends that shareholders accept the ANI Egetis offer. Shareholders holding about 42.2 per cent of the shares have undertaken to accept, subject to conditions.

What is ANI paying in the ANI Egetis offer?

The headline price is SEK 11.25 per share in cash, according to the formal offer announcement. ANI will also pay SEK 65,750,817 in cash for an outstanding convertible with a principal of €3 million. Each outstanding warrant attracts SEK 6.99 in cash.

The parties give two total figures, and they measure different things. The offer announcement values the offer at about SEK 5,304 million. That figure covers all 464,965,562 outstanding shares, the convertible and the warrants. However, ANI’s press release uses a larger figure of about SEK 5.6 billion. That figure is stated as “including outstanding incentive programs”. ANI converts it to about $560 million at a 30-trading-day average USD/SEK rate of 9.9471. That rate is as of 3 November 2026.

Deal terms at a glance

Premiums and enterprise value

The offer announcement states three premiums, each with its own reference price. The price is about 12.6 per cent above the closing price of SEK 9.99 on 4 November 2026. That was the last trading day before the announcement. It is also about 27.0 per cent above the 60-day volume-weighted average price of SEK 8.86. Against the 180-day volume-weighted average of SEK 7.60, the premium is about 48.0 per cent.

ANI also states an enterprise value of about $434 million. That figure is adjusted for the estimated net proceeds of a priority review voucher sale. The voucher sale is described below.

What does ANI get from Egetis?

The main asset is Emcitate. The FDA approved it on 28 September 2026, according to Egetis’s US approval announcement. The US indication is peripheral thyrotoxicosis in adults and paediatric patients with monocarboxylate transporter 8 (MCT8) deficiency. The condition is also known as Allan-Herndon-Dudley syndrome. In Europe, ANI states that the European Commission approved Emcitate on 12 February 2025.

Egetis describes MCT8 deficiency as a rare, life-limiting, X-linked disorder. It is caused by mutations in the SLC16A2 gene. The approval release reports a median life expectancy of about 35 years. ANI states that the condition affects about one in 70,000 males.

The approval release lists the evidence behind the filing. It names the ReTRIACt trial, Triac Trial I and Triac Trial II. It also cites two Erasmus Medical Center studies and a US expanded access programme. According to that release, the US label carries a boxed warning against use for obesity or weight loss. The label also states that Emcitate is not recommended for primary hypothyroidism.

Egetis announced US commercial availability on 27 October 2026, saying the launch came ahead of its anticipated timelines. It is working with PANTHERx Rare Pharmacy, a specialty pharmacy. Its RareLink programme supports patients and caregivers with access and care coordination.

ANI says Emcitate holds New Chemical Entity exclusivity in the US. It also cites orphan drug exclusivity in the US and Europe. In addition, ANI points to an Orange Book-listed patent running into mid-2045. ANI estimates peak sales potential of more than $300 million in the approved indication. That is a company estimate rather than an independent forecast.

Why do the parties say they agreed the deal?

ANI presents the deal as a step in its move into rare disease. Its release says the deal “Accelerates ANI’s strategic transformation into a leading Rare Disease company”. ANI also says it adds a new growth driver with a runway into 2045. Nikhil Lalwani, President and Chief Executive Officer, ANI, said: “This proposed acquisition further accelerates our transformation.”

The offer came on the same day as ANI’s third quarter results. In those results, ANI cut its 2026 Cortrophin Gel revenue guidance to $480 million to $500 million. The previous range was $520 million to $540 million. ANI cited slower revenue conversion due to specialty pharmacy capacity constraints.

The Egetis board statement gives its own reasons. It cites the company’s growth prospects and the risks attached to them. Those risks include “the costs and execution risk of a standalone U.S. commercial build-out and launch of EMCITATE”. The board also says ANI’s rare disease platform could make Emcitate available to more patients.

The statement also explains how the offer arose. Egetis ran a competitive process with its financial adviser. That process followed “the receipt of an unsolicited, non-binding indicative proposal to acquire Egetis”.

The priority review voucher

The FDA granted Egetis a rare paediatric disease priority review voucher with the Emcitate approval. On 4 November 2026, Egetis agreed to sell the voucher for $190 million in gross proceeds. The release does not name the buyer. The sale is subject to customary conditions, including expiry of the Hart-Scott-Rodino waiting period.

Egetis will not keep all of the money. Former owners of Rare Thyroid Therapeutics International have an earn-out of about 50 per cent of net proceeds. According to the release, that earn-out stems from Egetis’s 2020 acquisition of Emcitate. ANI says its offer price fully reflects the net value of the voucher on those terms.

When will the ANI Egetis offer close?

No completion date has been fixed. Instead, the offer announcement sets out an indicative timetable. ANI expects to publish an offer document shortly before the acceptance period begins. That period is expected to start on or around 20 November 2026. It is expected to end on or around 18 December 2026. ANI expects to declare the offer unconditional on or around 21 December 2026. Settlement is then expected to begin on or around 29 December 2026. ANI may extend the acceptance period and postpone settlement.

Conditions that must be met first

The main condition of the ANI Egetis offer is a 90 per cent threshold. ANI must become the owner of more than 90 per cent of Egetis shares on a fully diluted basis. All necessary regulatory clearances must also be received. These include competition and foreign direct investment approvals. ANI expects those approvals before the acceptance period expires. Other conditions cover a competing offer, a material adverse effect and Egetis’s disclosures. ANI may waive conditions, including the 90 per cent threshold.

The undertakings provide a base, but not certainty. Six shareholders hold the 42.2 per cent covered by undertakings. Frazier Life Sciences is the largest, with about 16.65 per cent. Cidro Förvaltning holds about 10.08 per cent. According to ANI’s Form 8-K, the undertakings lapse if the offer is not unconditional by 31 March 2027. They also fall away if a rival offer over 5 per cent higher goes unmatched for ten business days.

If ANI passes 90 per cent, it intends to start compulsory redemption under the Swedish Companies Act. It would then seek to delist Egetis from Nasdaq Stockholm.

Financing and advisers

ANI says the offer is funded from cash on hand and new debt from JPMorgan Chase Bank. Its Form 8-K describes a 364-day senior bridge facility of up to $676 million. The credit agreement is dated 4 November 2026, with JPMorgan Chase Bank as administrative agent. The facility can also refinance ANI’s existing term loans and certain Egetis debt.

Jefferies is sole financial adviser to ANI. Ropes & Gray and Mannheimer Swartling are its legal counsel. Centerview Partners is sole financial adviser to Egetis, with Vinge as its legal adviser.

How does the deal fit the wider market?

At about $560 million, the ANI Egetis offer falls outside LSDN’s tracker of 2026 biotech deals above $1 billion. Its structure is also simpler than many licensing deals. It is an all-cash public offer, and no milestones or contingent value rights are stated. By contrast, licensing headline totals often bundle upfronts, milestones and royalties, which makes comparisons harder.

Analyst comment so far is limited. In a quick comment on 5 November, Pareto said it did not expect a competing bid. That was reported by the Swedish news agency Nyhetsbyrån Direkt. Pareto pointed to the 42.2 per cent covered by undertakings. It also said it had underestimated what a strategic buyer would pay. That is a single broker view.

What to watch next

Several dated steps will show whether the ANI Egetis offer completes. The first is the offer document, expected shortly before about 20 November. The second is the outcome of competition and foreign direct investment filings. The third is the acceptance level when the period ends around 18 December. Separately, the voucher sale must clear its Hart-Scott-Rodino waiting period. Early US uptake of Emcitate will be the first test of ANI’s peak sales estimate.

Until settlement, Egetis remains an independent company listed in Stockholm. The ANI Egetis offer could still lapse if its conditions are neither met nor waived.